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This is Why we do Randomised Trials!Those who participated in the GALA (General vs Local
Anaesthesia) Trial are to be congratulated, not only for
having completed the largest ever randomised trial
involving carotid endarterectomy (CEA), but also for having
demanded that ‘level I evidence’ rather than ‘intuitive
reasoning’ resolve a controversial issue in contemporary
carotid surgical practice.1 The final results may not be quite
what the founders of this trial expected, but they can be
comforted by the fact that they are not alone. The history
of medicine is littered with examples of where the results
of randomised trials prove contrary to ‘expert opinion’ and
meta-analyses of non-randomised publications.
David Kent likened this phenomenon to the ‘shimmer
effect’ where increasingly greater claims are made for
a product/treatment, only for these to be rejected
following critical scientific scrutiny.2 In an editorial
accompanying a paper suggesting that peri-operative statin
usage reduced the risk of stroke during CEA, Kent reminded
the reader of the increasing evidence (including meta-
analyses3) that administering hormone replacement
therapy (HRT) to post-menopausal women in order to
reduce major cardiovascular events was so compelling that
it might even be unethical to consider performing a rando-
mised trial. Yet when such a trial was undertaken (the
Heart and Estrogeneprogestin Replacement Study (HERS)4),
it showed that not only did HRT not reduce the cardiovas-
cular risk, it actually increased the risk of thromboembolic
events.
Closer to home, some prominent vascular surgeons were
opposed to the need for performing randomised trials
comparing CEA with ‘best medical therapy’ in patients with
asymptomatic carotid disease. To them, the published
evidence was similarly compelling. However, following
publication of the Asymptomatic Carotid Atherosclerosis
Study (ACAS) in 1995, respected voices in the vascular
surgical community later admitted that, while ACAS had
shown a small but significant benefit favouring CEA, the late
stroke risk in patients randomised to medical therapy was
very much less than had been anticipated from the
preceding non-randomised, observational studies in the
literature.5 Similarly, large scale randomised trials have
determined that outcomes following eversion CEA are no1078-5884/$34 ª 2008 Published by Elsevier Ltd on behalf of European
doi:10.1016/j.ejvs.2008.10.010different to those following traditional CEA6 (provided the
latter involves patch closure of the arteriotomy site) and
that routine patch closure is safer than a policy of routine
primary closure.7 These examples of Level I evidence are
really important should vascular surgeons be challenged
(medicolegally) regarding aspects of their carotid surgical
practice. What a shame, therefore, that debate regarding
the remaining ‘titans’ of carotid practice (routine vs
selective patching/shunting) will never be resolved by
randomised comparison.
If nothing else, GALA has reminded the surgical
community of the fact that well conducted randomised
trials provide much better quality evidence than observa-
tional studies that are inevitably prone to inherent biases.
In this respect, readers are strongly recommended to read
Bruce Campbell’s excellent chapter on how data can be
‘manipulated’ in order to produce better outcomes.8
Only as recently as last week, the Cochrane Group pub-
lished its 2008 systematic review of nine randomised trials
(812 operations) comparing general and locoregional
anaesthesia (excluding GALA) as well as outcomes from 47
non-randomised studies involving no fewer than 24,181
patients.9 A meta-analysis of the randomised trials again
showed no evidence that CEA under locoregional anaesthesia
reduced the risk of procedural stroke. However, a systematic
review of the non-randomised trials showed significant
reductions in stroke (38/47 studies), death (42/47 studies),
stroke or death (27/47 studies), myocardial infarction (27/47
studies) and pulmonary complications (7/47 studies). In the
GALA trial (with 3526 randomised patients), none of these
endpoints found any statistically significant association
favouring locoregional anaesthesia (LRA).
The overall 30-day mortality rate in GALA was 1.5% in GA
patients vs 1.1% in those randomised to LRA. The death/
stroke rate was 4.6% (GA) vs 4.2% (LRA), while the 30-day risk
of death/stroke and MI (the primary endpoint in this study)
was 4.8% (GA) vs 4.5% (LRA). There were a number of other
interesting analyses published in GALA. The rate of
myocardial infarction was 0.2% where GAwas used vs 0.5% for
patients undergoing CEA with LRA. Given the prevailing
opinion prior to GALA that surgery under LRA reduced peri-
operative cardiac morbidity, this was a somewhat surprisingSociety for Vascular Surgery.
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length of hospital stay or use of HDU/ITU facilities relative to
choice of anaesthesia and no significant difference in
endpoints in a series of prespecified subgroups (patients
aged>75 years, patients scored as having increased surgical
risk). Interestingly, there was a non-significant trend towards
better outcomes in patients undergoing CEA under LRA if
they had a contralateral occlusion (difficult to know how to
interpret this given the small numbers involved), while the
one-year survival rates were non-significantly higher in
patients undergoing their CEA under LRA, an observation
that is similarly hard to currently explain.
The GALA trial is, however, notable for what it has not
revealed. Was there any difference in outcome in symp-
tomatic vs asymptomatic patients? GALA claims that their
surgical results represent an improvement on the earlier
ECST and NASCET studies, but stratification for symptom
status has not yet been released into the public domain.
Similarly, we have not been provided with any information
regarding the timing of procedure related strokes. The
rationale underlying CEA under LRA is that it will accurately
identify patients with inadequate collateralisation that
then require shunting so as to reduce the risk of haemo-
dynamic stroke. Accordingly, did patients randomised to
LRA suffer fewer intra-operative strokes? Were there any
patterns regarding the timing of post-operative strokes
(some have postulated that general anaesthesia may
increase a patient’s thrombotic risk)? Finally, and of most
practical importance to this observer, did CEA under LRA
reduce the incidence and need for treatment for post-
operative hypertension, a condition seen relatively
commonly in patients undergoing CEA under general
anaesthesia?
So how should these results be interpreted? First and
foremost, surgeons may continue to perform CEA under
general or locoregional anaesthesia (as to their preference)
without fear of being criticised on the basis of evidence. As
was succinctly stated by Pettiti,10 ‘‘experimentation
trumps observation’’. Second, it is reassuring to know that
other than a slight prolongation of the operation time, CEA
under LRA involving trainee surgeons and anaesthetists
was not associated with any excess risk. Accordingly,
surgeons/anaesthetists who are currently unfamiliar with
LRA may now feel more confident about introducing this
technique into their practice if they wish. Third, surgeons
cannot be pressurised by managers and accountants in to
performing CEA under LRA purely on the basis that this will
reduce hospital costs through reduced ITU/HDU and overall
length of hospital stay, as was implied in a number of non-
randomised studies. Fourth, is the simple fact that surgeons
must accept that if they wish to use a policy of selective
shunting then they must start performing CEA under LRA. It
is an indisputable fact that CEA under LRA will always be
the ‘gold standard’ for identifying patients who definitely
need a shunt. No other monitoring technique comes close in
terms of accuracy and safety (or ever will) and this debate
should really now be ended.Will I be changing practice? No. I remain a committed
‘routine shunter’ and have never subscribed to the belief
that shunts cause as many strokes as they prevent. It is my
contention that there are many more important aspects for
understanding and preventing procedural strokes.11
I would, however, add one important caveat to this
conclusion. If it can be shown that CEA under LRA reduces
post-operative hypertension, I would definitely be more
motivated to change an anaesthetic practice that has
worked very well in this Institution. Come on GALA, give us
this information!
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